Uncategorized

Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Building upon their partnership announced last year, digital health leader Dawn Health and global pharmaceutical company Novartis are proud to announce the launch of Ekiva PNH, an innovative digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria.

Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH) Read More »

Las fases de Venus

Entre las maravillas del cosmos, pocas rivalizan en belleza y misterio con las fases cambiantes de Venus, nuestro vecino planetario más brillante. Desde la antigüedad, los astrónomos han observado con asombro cómo Venus exhibe una variedad de formas en su apariencia a lo la …

Las fases de Venus Read More »

AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting

Ascentage Pharma announced that it releases the latest results from three preclinical studies of its novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and embryonic ectoderm development inhibitor APG-5918, at the 2024 American Association of Cancer Research Annual Meeting.

AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting Read More »

Scroll to Top